Home > Boards > US Listed > Biotechs > PDS Biotech (PDSB)

TheFly.comPortfolio Alerts

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
lidopete Member Profile
 
Followed By 0
Posts 552
Boards Moderated 0
Alias Born 07/16/06
160x600 placeholder
PDS Biotechnology Announces Conference Call and Webcast to Present Third-Quarter 2021 Financial Results GlobeNewswire Inc. - 10/13/2021 4:30:00 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/12/2021 4:30:58 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/6/2021 8:46:31 AM
PDS Biotechnology Welcomes Matthew Hill as Chief Financial Officer GlobeNewswire Inc. - 10/6/2021 8:30:00 AM
PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer GlobeNewswire Inc. - 10/4/2021 8:30:00 AM
PDS Biotechnology to Present at the Benzinga Healthcare Conference GlobeNewswire Inc. - 9/27/2021 8:30:00 AM
PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference GlobeNewswire Inc. - 9/22/2021 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/20/2021 8:45:44 AM
PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Advanced Head and Neck Cancer GlobeNewswire Inc. - 9/20/2021 8:30:00 AM
PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire Inc. - 9/15/2021 8:30:00 AM
PDS Biotechnology to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit  GlobeNewswire Inc. - 9/13/2021 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/9/2021 4:07:37 PM
PDS Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer GlobeNewswire Inc. - 9/9/2021 8:30:00 AM
PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference GlobeNewswire Inc. - 9/7/2021 8:30:00 AM
3 Monster Growth Stocks That Are Still Undervalued TipRanks - 8/30/2021 10:48:28 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 8/27/2021 8:49:25 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/12/2021 7:17:29 AM
PDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results GlobeNewswire Inc. - 8/12/2021 7:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2021 4:07:18 PM
PDS Biotechnology to Present Recent Phase 2 Human Clinical Data and On-Going Oncology Programs at Investor Conferences GlobeNewswire Inc. - 7/28/2021 8:00:00 AM
PDS Biotechnology Announces Conference Call and Webcast to Present Second Quarter 2021 Financial Results GlobeNewswire Inc. - 7/26/2021 8:00:00 AM
PDS Biotechnology added to Russell Microcap Index Seeking Alpha - 7/1/2021 9:16:41 AM
PDS Biotechnology Joins Russell Microcap® Index GlobeNewswire Inc. - 7/1/2021 8:30:00 AM
Intellia in focus after landmark trial data, Unity Biotech wins double upgrade: in today's analyst action Seeking Alpha - 6/28/2021 8:25:17 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 6/21/2021 5:02:47 PM
lidopete   Wednesday, 06/09/21 07:13:04 AM
Re: None
Post # of 1549 
TheFly.com

Portfolio Alerts
Click the Portfolio Name or Symbol to see the research on thefly.com
Main Portfolio matches: PDSB.

TODAY, JUNE 09, 2021
PDSB
07:05
Recommendations
PDS Biotechnology price target raised to $18 from $6.50 at Alliance Global Partners
Alliance Global Partners analyst James Molloy raised the firm's price target on PDS Biotechnology to $18 from $6.50 and keeps a Buy rating on the shares after the company reported additional data from its ongoing PDS0101 Phase 2 triple combination trial in HPV-related cancers at ASCO. He has lowered his discount rate on expected future royalty payments and is now including a separate valuation for PDSB0101 given the recent promising HPV triple combination data and "promising results" from PDS' proprietary Versamune platform, Molloy tells investors.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences